483
Aquestive TherapeuticsAquestive Therapeutics – FDA 483, Jan 30, 2025
Record Details
An FDA inspection of Aquestive Therapeutics in Portage, Indiana, revealed two significant observations. The firm failed to thoroughly investigate product complaints, specifically regarding white spots on SUBOXONE® sublingual film, and lacked adequate corrective and preventive actions. Additionally, the company did not have sufficient systems in place to comply with the Drug Supply Chain Security Act's verification requirements for suspect and illegitimate products.
View Company Profile
ID · 986d4495-7f77-47ff-acec-d2c38ff0c2ab
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.